Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer

Journal of Clinical Medicine
Ines PombeiroChristoph Roderburg

Abstract

The tumor necrosis factor⁻related weak inducer of apoptosis (TWEAK) belongs to the tumor necrosis factor ligand superfamily, which was shown to play an important role in inflammatory and malignant gastrointestinal diseases, including colitis or colorectal cancer. However, in contrast to other members of the TNF ligand superfamily, its role as a biomarker in pancreatic cancer is currently unknown. We analyzed serum levels of A proliferation-inducing ligand (APRIL) and TWEAK in 134 patients with pancreatic cancer. Results were compared with 50 healthy controls and correlated with clinical data. Intratumoral expression of APRIL and TWEAK in pancreatic cancer was analysed using the datasets made available by the TCGA-LIHC project. APRIL serum levels were significantly elevated in patients with pancreatic cancer compared to healthy controls, which is in line with previous findings. Notably, the diagnostic accuracy of circulating APRIL levels was similar to CA19-9, an established tumor marker for pancreatic cancer. In contrast, serum concentrations of TWEAK were decreased in pancreatic cancer patients. Interestingly, no differences in TWEAK concentrations became apparent between different clinical subgroups of pancreatic cancer. More...Continue Reading

References

Jul 23, 1999·Annals of the New York Academy of Sciences·H FriessM W Büchler
Dec 6, 2000·The Journal of Experimental Medicine·C F Ware
May 12, 2005·Cancer Letters·Jeffrey A WinklesMichael E Berens
Jul 11, 2006·Immunology·Stéphanie HaiatJean-Pierre Kolb
Nov 14, 2006·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·K S Goonetilleke, A K Siriwardena
Nov 28, 2006·Frontiers in Bioscience : a Journal and Virtual Library·Jeffrey A WinklesMichael E Berens
Oct 31, 2009·European Journal of Heart Failure·Emmanuel ChorianopoulosNorbert Frey
Oct 5, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Christoph RoderburgTom Luedde
May 27, 2011·Clinical Chemistry and Laboratory Medicine : CCLM·Feng WangHuimin Wang
Mar 27, 2012·Expert Opinion on Therapeutic Targets·Carmine Carbone, Davide Melisi
Jan 1, 2011·Experimental and Therapeutic Medicine·Ryo YorikiYoshiyuki Nakajima
Aug 7, 2013·The Journal of Cell Biology·Geou-Yarh LiouPeter Storz
Aug 21, 2013·British Journal of Pharmacology·Harald Wajant
Dec 5, 2014·Oncotarget·Lakshmi PrabhuTao Lu
Feb 3, 2016·Lancet·Terumi KamisawaKyoichi Takaori
May 4, 2016·JAMA : the Journal of the American Medical Association·Deborah Schrag
Oct 22, 2016·Current Opinion in Cell Biology·Marina Pesic, Florian R Greten
Oct 7, 2016·Clinical and Translational Medicine·Sven H LoosenTom Luedde
Jun 18, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Sven H LoosenTom Luedde
Sep 5, 2017·Cancer Treatment Reviews·Marta ChiaravalliEileen M O'Reilly

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques
enzyme-linked immunosorbent assay
ELISA

Software Mentioned

GraphPad Prism
APRIL
TWEAK
SPSS

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis